Drug Profile
Research programme: therapeutics for neuropsychiatric and neurodevelopmental disorders - AstraZeneca/Lieber Institute for Brain Development
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator AstraZeneca; Lieber Institute for Brain Development
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Mental disorders
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Mental-disorders in USA
- 03 Dec 2013 Early research in Mental disorders (neuropsychiatric and neurodevelopmental disorders) in USA (PO)